High Throughput Genomics Appoints Jerry Zemaitis VP of Commercial Operations
News Aug 16, 2007
High Throughput Genomics, Inc. has announced the appointment of Jerry Zemaitis, Ph.D. to the position of vice president of commercial operations.
In this newly created position, Zemaitis will be responsible for forming strategic agreements with academic institutions, cultivating new business partnerships and establishing relationships with distributors in the U.S. and internationally.
Zemaitis joins HTG from Zeta Strategic Consulting, a consulting firm that specializes in business planning and marketing for life sciences and telecommunications companies, where he was founder and principal consultant.
“HTG’s assay technology has immense potential to accelerate the drug discovery process and bring new drugs to market faster,” said Jerry Zemaitis, Ph.D., vice president of commercial operations, HTG. “qNPA enables scientists to refocus on the biology and empowers them to make better decisions with higher confidence.”
Zemaitis earned a B.A. in biology from Rutgers, The State University of New Jersey and did graduate work in biochemistry at the University of Medicine and Dentistry of New Jersey.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE